Vitamins? The magic bullet against hepatitis C. (Q50550106)

15 March 2018

title

Vitamins? The magic bullet against hepatitis C. (English)

1 reference

15 March 2018

author name string

Hans L Tillmann

series ordinal

1 reference

15 March 2018

publication date

1 November 2012

1 reference

15 March 2018

Expert Review of Anti-infective Therapy

published in

1 reference

15 March 2018

volume

1 reference

15 March 2018

issue

1 reference

15 March 2018

page(s)

1273-1277

1 reference

15 March 2018

Vitamin B12 and hepatitis C: molecular biology and human pathology

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.127

Vitamin B12 stalls the 80 S ribosomal complex on the hepatitis C internal ribosome entry site

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.127

Differential effects on the hepatitis C virus (HCV) internal ribosome entry site by vitamin B12 and the HCV core protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.127

Serum B12 levels predict response to treatment with interferon and ribavirin in patients with chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.127

Comparison of qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and quantitative (COBAS AMPLICOR HCV monitor 2.0 versus VERSANT HCV RNA 3.0) assays for hepatitis C virus (HCV) RNA detection and quantification: impact on diagnosis and treat

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.127

Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.127

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.127

Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.127

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.127

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.127

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.127

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.127

Homocysteine levels and sustained virological response to pegylated-interferon alpha2b plus ribavirin therapy for chronic hepatitis C: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.127

Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.127

Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.127

Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.127

Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.127

Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.127

A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.127

Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.127

Holotranscobalamin, a marker of vitamin B-12 status: analytical aspects and clinical utility

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.127

Biomarkers of vitamin B-12 status in NHANES: a roundtable summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.127

The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.127

Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.127

Comprehensive Analysis of the Effects of Ordinary Nutrients on Hepatitis C Virus RNA Replication in Cell Culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.127

Metabolic Syndrome Is Also a Risk Factor for Primary Liver Cancer in Patients Younger than 65 Years of Age?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.127

Holotranscobalamin is a useful marker of vitamin B12 deficiency in alcoholics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.12.127

21 January 2018

Identifiers

DOI

10.1586/ERI.12.127

1 reference

15 March 2018

1 reference

15 March 2018